| Michael Sean Dewolfe, MD | |
|
3249 Oak Park Ave, Berwyn, IL 60402-3429 | |
| (708) 783-9100 | |
| Not Available |
| Full Name | Michael Sean Dewolfe |
|---|---|
| Gender | Male |
| Speciality | Plastic And Reconstructive Surgery |
| Experience | 23 Years |
| Location | 3249 Oak Park Ave, Berwyn, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538307566 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208200000X | Plastic Surgery | 036120425 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventist Hinsdale Hospital | Hinsdale, IL | Hospital |
| Macneal Hospital | Berwyn, IL | Hospital |
| Entity Name | Loyola Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376041954 PECOS PAC ID: 6305109547 Enrollment ID: O20180420002063 |
News Archive
Abortions-Rights advocates are pressing lawmakers through new ad campaigns to keep a provision restricting abortion coverage in the House-passed health bill - the so-called Stupak amendment - out of the Senate health care bill, CBS News reports.
Patients with esophageal cancer who refuse surgery when it is recommended are less likely to survive long term than similar groups of patients who undergo an operation, according to research presented today at the 54th Annual Meeting of The Society of Thoracic Surgeons.
Studies show that up to 35 percent of cancer patients are at risk for an allergic reaction to their cancer therapy. Yet, the same drug causing the reaction could be the drug that best helps to control the disease.
Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, will announce results from its Phase 2/3 clinical trial of its proprietary inhaled alpha-1 antitrypsin (AAT) to treat alpha-1 antitrypsin deficiency (AATD) in Europe and Canada on Friday, May 16, 2014, at approximately 7:30 a.m. Eastern time.
› Verified 3 days ago
| Entity Name | Dewolfe Aesthetic Services Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467074617 PECOS PAC ID: 8224452628 Enrollment ID: O20200717002212 |
News Archive
Abortions-Rights advocates are pressing lawmakers through new ad campaigns to keep a provision restricting abortion coverage in the House-passed health bill - the so-called Stupak amendment - out of the Senate health care bill, CBS News reports.
Patients with esophageal cancer who refuse surgery when it is recommended are less likely to survive long term than similar groups of patients who undergo an operation, according to research presented today at the 54th Annual Meeting of The Society of Thoracic Surgeons.
Studies show that up to 35 percent of cancer patients are at risk for an allergic reaction to their cancer therapy. Yet, the same drug causing the reaction could be the drug that best helps to control the disease.
Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, will announce results from its Phase 2/3 clinical trial of its proprietary inhaled alpha-1 antitrypsin (AAT) to treat alpha-1 antitrypsin deficiency (AATD) in Europe and Canada on Friday, May 16, 2014, at approximately 7:30 a.m. Eastern time.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Sean Dewolfe, MD 728 W Jackson Blvd Apt 219, Chicago, IL 60661-5534 Ph: (312) 890-8198 | Michael Sean Dewolfe, MD 3249 Oak Park Ave, Berwyn, IL 60402-3429 Ph: (708) 783-9100 |
News Archive
Abortions-Rights advocates are pressing lawmakers through new ad campaigns to keep a provision restricting abortion coverage in the House-passed health bill - the so-called Stupak amendment - out of the Senate health care bill, CBS News reports.
Patients with esophageal cancer who refuse surgery when it is recommended are less likely to survive long term than similar groups of patients who undergo an operation, according to research presented today at the 54th Annual Meeting of The Society of Thoracic Surgeons.
Studies show that up to 35 percent of cancer patients are at risk for an allergic reaction to their cancer therapy. Yet, the same drug causing the reaction could be the drug that best helps to control the disease.
Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, will announce results from its Phase 2/3 clinical trial of its proprietary inhaled alpha-1 antitrypsin (AAT) to treat alpha-1 antitrypsin deficiency (AATD) in Europe and Canada on Friday, May 16, 2014, at approximately 7:30 a.m. Eastern time.
› Verified 3 days ago